

Bone mineral density and bone turnover markers in children with Haemophilia A

P. Xafaki¹, H. Pergantou¹, A. Doulgeraki², H. Athanasopoulou², H. Platokouki¹

¹Haemophilia Centre/Haemostasis Unit, "Aghia Sophia" Children's Hospital, Athens, Greece

² Institute of Child Health, "Aghia Sophia" Children's Hospital, Athens, Greece

OBJECTIVES

Persons with Haemophilia might have a predisposition for low bone mineral density because of recurrent hemarthroses, prolong immobilization and limited physical activity.

Bone status evaluation

✓Dual energy X-Ray absorptiometry (DXA) is the gold standard for bone mineral density (BMD) measurement (static evaluation)

✓Bone turnover markers are specific bone-derived molecules that reflect the bone metabolic activity (dynamic evaluation)

Aim

- To assess bone mineral density (BMD) using dual-energy X-Ray absorptiometry (DXA)
- To investigate possible correlations of DXA findings with serum markers of bone turnover in children with Haemophilia A

METHODS

A. Dual energy X-Ray absorptiometry (DXA)

- Total body (TB) and/or lumbar spine (LS) scanning was applied for BMD measurement
- Bone Mineral Density (BMD) expressed as **z-score**, according the Official Position of International Society for Clinical Densitometry, ISCD 2007
- z-score is defined as the number of SD above or below the mean, determined using age- and gender-matched reference data (**z-score < -2, established as low BMD for chronological age**)

B. Bone turnover markers

Bone resorption markers

- urinary deoxypyridinoline/creatinine (uDPD/uCr, nmol/mmol cr)
- urinary excretion of calcium (uCa/uCr, mmol/mmol)
- tartrate-resistant acid phosphatase (Trap, ng/ml)

Bone formation markers

- serum total alkaline phosphatase (ALP, IU/L)
- bone specific alkaline phosphatase (bALP, IU/L)
- osteocalcin (OC, ng/ml)
- carboxy-terminal propeptides of type I collagen (PICP, ng/ml)

Other

- Vitamin D (25OHD), parathormone (PTH)
- serum Ca (mmol/l) and urinary excretion of phosphorus (uP/uCr)


RESULTS

I) Demographic data

51 children with Haemophilia A were included in the study
41 children had severe type of the disease (FVIII<1 iu/dl)
mean age:11.7±3.6 years (range 7-19)
on prophylaxis:43/51 patients (secondary in the majority of the cases)

II) LS and TB BMD z-scores

	Mean z-score	Z-score between -1 and -2	Z-score <-2
LS BMD (40 children)	-0.51±0.98	8/40 children (20%)	4/40 children (10%)
TB BMD(44children)	0.18±0.85	4/44 children (9.1%)	-




III) Bone formation markers

- Osteocalcin levels were significantly decreased in the patients compared to a standard control group (19.06±5.8 vs 22±10.8, p<0.05), whereas the other bone formation markers were within normal range. Fig 1
- OC was positively correlated with LS and TB z-scores (r=0.337 and r=0.313 respectively, p<0.05). Fig 2a,b


Group	N	Mean	Std. Deviation	P
ALP	Patients 51	351,6	99,3	NS
Controls 40	348,0	137,9		
bALP	Patients 50	115,3	53,5	NS
Controls 51	117,0	63,2		
OC	Patients 50	19,0	5,8	<0.05
Controls 49	22,0	10,8		
PICP	Patients 50	161,6	96,9	NS
Controls 49	173,5	139,0		

Fig. 1



IV) Bone resorption markers

- 38/49 children (77.6%) had increased uDPD/uCr (mean:32.35±14.6, n.v <22)
- The patients with abnormal levels of uDPD/uCr had lower LS z-scores (mean -0.82±0.85 vs -0.20±0.97, p<0.05) and TB z-scores (mean -0.08±0.69 vs 0.37±0.91)
- No significant differences were detected in uCa/uCr and bone Trap.
- uDPD/uCr inversely correlated with LS BMD (r=-0.677) and TB BMD (r=-0.569), p<0.01. Fig 3a,b



- V) Decreased **vitamin D** levels (mean 27.9±19.33, normal values >20ng/ml) were found in 18/49 children (36.7%). No differences were observed in z-scores between children with adequate or not vitamin D levels.

CONCLUSIONS

In our study, 30% of children with Haemophilia A had low for chronological age Lumbar Spine Bone Mineral Density, not related to vitamin D levels. Almost 80% of them had increased uDPD/uCr (bone resorption marker), without parallel increase of bone formation markers. Haemophilic children are prone to develop bone metabolic disturbances; thus, close monitoring of bone status and therapeutic intervention, if required, might be beneficial for long term outcomes.

